Tag: Funding

Categories
Digital Health MedTech

Europe MedTech & Digital Health Weekly Brief (Week of September 6–12, 2025, #5)

Workflow AI meets hard regs: funding into clinical workforce & pathology AI, a CEE mental health roll-up, and CE marks in resuscitation, MSK and neuro-mobility.

People on the move

Haughton Design (UK) appoints Dr. Ash Ghadar as CEO to scale medtech/drug-delivery design services; a reminder that device commercialisation chops are in demand.

Allianz Partners (FR) names Okan Özdemir Chief Officer for Health & Board Member; payer-side signal for digital health distribution.

Money flows

Teton.ai (DK) $20M Series A, predictive eldercare AI; Plural leads with Bertelsmann Investments, Antler Elevate, Nebular and PSV Tech. Funds to push EU/US rollout and dataset expansion.

TERN Group (UK) €20M Series A; AI clinical workforce platform to optimise staffing across Europe & GCC; led by Notion Capital with RTP Global, LocalGlobe, EQ2, Leo Capital et al.

Aiosyn (NL) €2.4M to advance AI pathology tools for cancer diagnostics; supports validation and productisation with Dutch partners.

SafeHeal (FR) €10M Series C extension led by Asabys to accelerate EU commercial launch of Colovac and continue U.S. study.

Hedepy (CZ) acquires Poland’s HearMe (terms undisclosed) to consolidate CEE online psychotherapy; adds 80+ corporate clients and 120+ professionals; founders join leadership

On the press

• Neurescue (DK) wins CE mark under MDR for its intelligent aortic balloon catheter; the first device approved to treat non-shockable cardiac arrest in Europe.

• Varian (Siemens Healthineers) secures CE mark for Embozene microspheres in genicular artery embolisation (GAE) for knee osteoarthritis; first CE-marked embolic for GAE.

• Lifeward (IL/US) gains CE mark for ReWalk 7 personal exoskeleton; EU commercial launch enabled, with Germany a key reimbursed market.

• Report: Europe’s 10 biggest healthtech deals in H1 2025: €4B raised; UK led by volume. Useful late-stage context.

One thing to remember

Regulatory traction is back: three CE marks in one week (resuscitation, MSK pain, neuro-mobility) while capital flowed to workflow AI (staffing, lab data) and pathology. EU buyers will reward products that unblock staffing, data, and function bottlenecks.

This content has been enhanced with GenAI.

Categories
MedTech

Quantum & Supercomputers: How Hybrid Computing Could Shave Decades off MedTech R&D

Quantum and Supercomputers hybrid in MedTech R&D

Think AI alone is transforming healthcare? Think again. The real game-changer could be quantum computing, particularly when paired with supercomputers. This isn’t future fiction anymore. It’s happening now.

What’s New—and Why It Matters

Combining quantum computing and supercomputers enables molecular simulations, like insulin dynamics involving tens of thousands of orbital. Classical systems simply could not handle it.

Experts are calling this the “AI on steroids” era, and the real test is whether quantum hardware can catch up to the hype.

Expected impact: quantum systems promise to make drug development far more accurate and efficient than ever before.

Strategic Insight—Why It Matters for European Commercialisation

  • Regulation won’t slow us down: Quantum tools could help Europe leapfrog red tape by enabling faster, in-silico trials and predictive toxicology.
  • Startups must recalibrate: As this tech moves from testing labs to real-world deployment, funding and venture strategies must shift, think hybrid infrastructure, not cloud-only or chip-only bets.
  • Policy windows opening: EU research programmes (e.g., Horizon Europe, Digital Europe) could be primed to support hybrid computing capabilities as they realise their impact on healthcare ROI.

What Are the Challenges? (Because of course there are.)

  • Hardware still nascent: Supercomputer capacity is real—but quantum hardware still lags and faces error-correction hurdles. “AI on steroids” isn’t quite combat-ready yet.
  • Integration complexity: Hybrid systems bring technical, regulation, and cost challenges, especially for SMEs.
  • Talent crunch: Few European researchers bridge computational chemistry, quantum algorithms, and AI. Building that capability will be critical.

Quantum‑supercomputer hybrids aren’t tomorrow’s sci‑fi. They’re today’s infrastructure for slashing decades off MedTech R&D. Don’t sleep on this. Europe’s commercial edge will go to those who code quantum-native, not just cloud‑native.

This content has been enhanced with GenAI.

Categories
Digital Health MedTech

Quantum Healthcare in Europe: Funding, Regulation and the Path to Market

Quantum Healthcare in Europe - Funding, Reugulations and Path to Market

Europe’s Quantum Moment

Europe is not just a consumer of quantum technologies, it’s investing heavily to become a global leader. The Quantum Technologies Flagship commits €1 billion over 10 years to research and commercial pilots.

Add Horizon Europe and EuroHPC’s hybrid supercomputers, and you get a uniquely European playbook: strong public co-funding, national champions, and cross-border infrastructure.

Key hubs include:

  • France: Pasqal, a neutral-atom hardware leader, and Qubit Pharma, focused on quantum drug discovery.
  • Germany: Fraunhofer institutes leading applied research and partnerships with IBM.
  • Finland: Algorithmiq, developing quantum algorithms for pharma and life sciences.

Regulation as Strategy

What makes Europe unique is not qubit counts but regulation as market infrastructure. For quantum healthcare, three frameworks matter most:

  • GDPR: mandates privacy and security by design, critical for sensitive genomic and clinical data.
  • Medical Device Regulation (MDR) & In Vitro Diagnostic Regulation (IVDR): quantum-enabled diagnostics must clear the same CE-marking hurdles as any AI-driven device.
  • AI Act: classifies healthcare AI (quantum or not) as “high-risk,” requiring transparency, bias monitoring, and human oversight.

For founders, this is not just a compliance burden but a potential export advantage: build under Europe’s strict rules, and your product is more likely to pass scrutiny in the US, UK, and Asia.

The Funding Landscape

European investors are cautiously optimistic. Quantum is a long game, but public–private models are de-risking the early stage. The European Investment Bank (EIB) has begun backing quantum startups, and national governments (e.g. France’s €1.8bn quantum plan) provide direct subsidies.

Still, private VC funding in Europe lags the US. The opportunity lies in co-investment: pairing deep-tech VCs with public grants to build resilient ventures that can survive the long runway to commercial ROI.

Strategic Takeaway

For Europe’s medtech and pharma founders:

  • Embrace regulation early: treat MDR, GDPR, and the AI Act as design inputs, not afterthoughts.
  • Leverage co-funding: combine EU and national grants with private capital to extend runway.
  • Anchor in hubs: partner with HPC centres, Fraunhofer, or national quantum labs to gain credibility.

Quantum healthcare in Europe won’t be won by the first to 1,000 qubits. It will be won by the first to regulation-ready, market-accessible solutions that can scale across 27 member states and then export globally.

Categories
Digital Health MedTech

Europe MedTech & Digital Health Weekly Brief (Week of August 30–September 5, 2025, #5)

Hospitals want evidence, investors want traction: this week mixed the two: GI diagnostics, insulin delivery, genomics M&A. And sprinkled in fresh CE marks for surgical robots.

People on the move

Data4Life (DE), a digital health nonprofit backed by SAP founder, Hasso Plattner, appoints Dr. Ben Illigens as CEO to steer its health data and research initiatives. Data4Life is building open source platform Data2Evidence, which is based on the international OMOP data model.

“We are at a turning point where digital technologies are fundamentally transforming research and care. My goal is to strengthen Data4Life as a bridge between clinical research, technology, and practice,”
Dr. Ben Illigens.

Lottie (UK): George Hadjigeorgiou, cofounder of ZOE, a personalized nutrition health company, joins the board of Lottie as NED, signaling deeper crossover between consumer health and eldercare ops. Lottie is a UK’s marketplace for care homes and care services.

Money flows

Kaleido Insulin Pump visualisation - Source: https://hellokaleido.com/

ViCentra (NL) — $85M Series D; insulin patch pump maker (Kaleido) fuels next-gen device development and scale-up.  Round was led by new investor Innovation Industries, a leading European deeptech venture capital firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations.

Cyted Health (UK) — €37.5M Series B; GI molecular diagnostics to improve early detection and prevention of oesophageal cancer. Round aims to expand US commercialization while consolidating NHS footprint. Investment led by EQT Life Sciences, Advent Life Sciences and British Business Bank with continued support from existing investors Morningside and BGF.

ArcaScience (FR): $7M round led by The Moon Venture; AI “benefit–risk” intelligence platform for life-sciences R&D to clean, link and query messy evidence.

Aiomics (DE) — €2M pre-Seed; clinical-grade AI agents to reduce clinical documentation burden and improve care pathways.

M2Care (FR): €26M venture-studio raise from Bpifrance’s FTA2 fund to create/develop eight healthtech projects. Other investors in M2Care are Mérieux Développement (who actully created this incubator), Institut NAOS des Sciences de la Vie, Crédit Agricole Centre-Est. 

SeqOne (FR) aquired Congenica (UK), on undisclosed terms.
This merger creates a larger AI-powered genomics software group with strong UK presence.

On the press

One thing to remember

Evidence-first commercialisation is back: capital flowed to diagnostics and chronic-care delivery while robotics snagged CE marks. A cross-border genomics deal underlined that European buyers will pay for software that shortens time-to-impact. If you’re fundraising, pair outcomes data with a path to multi-market reimbursement; if you’re buying, look for software that accelerates clinical workflows, not just visibility.

Categories
MedTech

€200 Million for Ortivity: Why Outpatient Orthopaedics Is Europe’s Quiet MedTech Power Play

Ortivity logo.

€200 million. Not a sum we see every day in European HealthTech, especially outside AI hype-cycles. Munich-based Ortivity broke the mould—raising a mega‑round led by Apheon, with new capital from Unigestion, allowing existing shareholders a partial exit.

What is Ortivity?

If you are not living in Germany, you probably never heard about it. Founded in 2022 Ortivity has over the past four years bacame one of Germany’s most prominent outpatient healthcare platforms. It operates over 100 sites across three regional clusters in Germany, offering a full spectrum of orthopaedic services, including diagnostics, anaesthesia, surgery, prevention, and aftercare.

Ortivity’s physician partnership model and emphasis on clinical excellence is unique. It is owned equally by physicians and capital providers.

Leadership & Founders: Meet the Faces Behind the Platform

Founding Doctors

Ortivity was launched in 2022 through a collaboration between Dr med Reinhard Wichels and Apheon, along with a network of leading physicians. Wichels framed the vision from day one as “physician networks closing gaps in access and quality,” a quote that still anchors the company’s ethos.

New Co-CEO: Dr Michael Thorwarth

Joining Ortivity as co‑CEO on 1 June 2025, Dr Michael Thorwarth brings dual expertise in medicine (MKG surgery), healthcare management (MBA), and consulting. Prior to Ortivity, he was a Partner at BCG, CEO at DEIN DENTAL, and Group CEO at Ergéa Group, a pan-European player in oncology, radiology and diagnostics.

Why This Round Matters

  • Mega‑scale in a cautious market: A €200 million deal in EU HealthTech is rare. It signals renewed investor confidence in service-oriented MedTech, beyond devices or AI.
  • Leadership reflects intent: Bringing on a seasoned strategist with transformation credentials like Thorwarth indicates clear intent to scale fast and structure for international growth.
  • Physician-led, but platform-focused: Ortivity’s buy‑and‑build model expanding into regional orthopaedic clusters in NRW, Bavaria, Baden-Württemberg shows a credible path to consolidation in a fragmented EU market

The Bigger Picture for EU MedTech

  • From cottage to platform: Europe’s MedTech strength has been in manufacturing devices, but scaling integrated care platforms remains elusive. Ortivity’s rise suggests that’s beginning to change.
  • Orthopaedics as export vertical: With ageing demographics, musculoskeletal care is a high‑demand field. A platform that delivers standards, scale, and efficiency across borders has global potential.
  • Private equity getting serious: Apheon remains the lead investor, indicating commitment and patience. With Unigestion joining, it’s clear the capital strategy is long‑term, not flip‑and‑sell

Takeaway

This isn’t just another €200 million HealthTech round. It’s a watershed moment for European MedTech. A proof that physician‑led outpatient platforms can attract serious capital, build organisational muscle and potentially export a scalable model.
And, ironically, the biggest disruption in health might come not from injecting AI into everything, but from getting people back on their feet: efficiently, compassionately, and at scale.

Categories
MedTech

OrganOx’s $1.5B Exit and Europe’s €403M MedTech Push: A Blueprint for Start-Up Success

OrganOx metra transport. Source: OrganOx website

Forget IPO hype. Europe’s MedTech scene is quietly reinventing exit strategies. The recent blockbuster OrganOx deal shows that patient-growth capital and global acquirers, not public markets, may set the real pace for scaling life-saving innovation.

OrganOx’s $1.5B Exit: A MedTech Precedent in a Quiet Market

Oxford-based OrganOx, a university spin‑out, has secured one of the UK’s largest MedTech exits, a $1.5 billion acquisition by Terumo. The deal delivered a 10× return for BGF, one of the UK’s most active investors. OrganOx’s technology, automated liver perfusion, has already supported over 6,000 transplants worldwide. In layman terms, it allows fors fully automated, easy-to-use preservation of the donor organ in a functional state for up to 24 hours.

In a market where IPOs have gone quiet, this deal sets a new precedent: high-value, clinically proven MedTech start-ups don’t need to chase the volatility of public markets to deliver impact and returns.

Europe’s MedTech Funding Engine: A Public‑Private Lever

The European Commission has approved a €403 million funding IPCEI programme for MedTech SMEs, with a focus on digital health and AI-enabled devices. The package is expected to attract €826 million in private capital and create 800 jobs across Europe.

For startups, this funding represents more than a financial lifeline: it’s a validation that EU policy is actively supporting MedTech innovation and aiming to rebalance Europe’s lagging venture ecosystem.

What This Means for Start-ups? Beyond IPOs to Real Outcomes

  • Exit without IPO: OrganOx proves that acquisition can be just as transformative as a listing.
  • Policy-driven growth: Founders should align their pipelines with EU funding priorities to maximise non-dilutive leverage.
  • Execution over hype: Europe rewards clinical validation and scalable access models—not moonshot projections.

Startups should design strategies that are M&A ready while embedding pathways to tap into EU-backed scaling opportunities.

Implications for Strategy and Investors

  • For founders: Patient growth capital and regulatory navigation matter more than vanity valuations. Position your business for strategic buyers who can unlock global reach.
  • For investors: The OrganOx exit underscores the value of holding through scale. In a funding environment tilted towards policy-supported growth, long‑term bets on MedTech SMEs can deliver double‑digit returns.

Conclusion

OrganOx isn’t just a headline; it’s a guidepost. In Europe’s MedTech world, execution and ecosystem alignment outperform aspiration for the trading floor. The lesson? IPO dreams may dominate headlines, but the real exits are happening elsewhere.

Categories
Digital Health MedTech

Europe MedTech & Digital Health — Weekly Brief (Week of Aug 16–22, 2025, #3)

AI meets approvals, mental health consolidates, and early-stage device builders get fuel — a tidy week for cardiology/ophthalmology AI, workflow rollouts, and surgical tools.

People on the move

CMR Surgical: Chris O’Hara joins as Commercial President & GM (U.S.) to drive Versius robot expansion following FDA authorization; signals Cambridge-based CMR’s acceleration of global go-to-market. Mr. O’Hara brings experience at Intuitive Surgical (a company that builds DaVinci that Versius robot is challenging) and Globus Medical (specialists in spine sugery devices), his appointment is a strategic bet from CMR Surgical.

Money flows

Nami Surgical (Glasgow, UK): $10M, Series A (opened); developing a mini ultrasonic scalpel for robotic surgery. Proceeds support product development and commercialization prep. Tech from Nami addresses a critical unmet need in the field. Ultrasonic scalpels, which use high-frequency vibrations to simultaneously cut tissue and cauterise blood vessels, are indispensable tools in modern minimally invasive surgery. What they have is 90% smaller than available competitors.

Mindler (Sweden) acquires ieso Digital Health UK on undisclosed terms; creates a cross-border digital mental health platform spanning Nordics & UK buyers (employers, insurers, public payers). As there is an urgent need to address crisis of mental health and lack of (human) specialists, platforms such us Mindler and ieso are indispensable.  Mindler is acquiring only ieso’s UK-based telecare services business, which is responsible for direct patient care delivery to the NHS. The parent company, ieso, will remain an independent entity pivoting to focus on the development and commercialisation of its evidence-based clinical AI platform, Velora, with an initial focus on the US market.

On the press

• ZEISS lands CE mark for CIRRUS PathFinder: integrated AI decision-support for OCT that flags abnormal macular B-scans and improves OCTA visualization; EU-ready software update/licence.

• Femasys secures UK MHRA approval for FemBloc: non-surgical, in-office permanent contraception; follows the company’s recent CE mark and advances European commercialization.

• Affidea x Skin Analytics: pan-European partnership to deploy Class III CE-marked AI dermatology (DERM – Deep Ensemble for the Recognition of Malignancy) across sites, starting in Romania and Lithuania with Greece next.

One thing to remember The EU’s AI-in-diagnostics momentum is real: new CE/MHRA greenlights (ZEISS, FemBloc) are pairing with deployment deals (Affidea × Skin Analytics), while funding still finds focused hardware/robotics and safety wearables (Nami Surgical, SIT). Founders: bring regulatory-grade proof and a crisp rollout plan.

This content has been enhanced with GenAI tools.

Categories
Digital Health MedTech

Europe MedTech & Digital Health — Weekly Brief (Week of Aug 9–15, 2025, #2)

A crisp week: AI diagnostics raised, sports concussion wearables funded, a Dutch conversational-AI startup got scooped up, and the UK nudged its devices policy closer to home care.

People on the move

Jade Leung - a new UK Prime Minister AI Adviser. Source: Linkedin

Jade Leung has been appointed as the UK’s Prime Minister’s AI Adviser while continuing as CTO at the AI Safety Institute; expect ripple effects on health AI policy and procurement.

Tom Moore - President and CEO of Minze Health

Thomas Moore named President & CEO of Minze Health to scale digital urology diagnostics/therapeutics across EU and the US.

Money flows

Sports Impact Technologies (Ireland): €650K Pre-Seed for behind-the-ear concussion-detection wearable; beta with athletes kicks off in September, full launch targeted for 2026.

Better Medicine (Estonia): €1M Pre-Seed to expand CE-certified AI for kidney cancer detection, fund EU rollout and FDA-aligned pilots.

VentriJect (Denmark) — €1.7M (round type undisclosed) to scale its cardiorespiratory fitness monitoring device (SEISMOfit) and push commercialization.

HOPCo × Caro Health (the Netherlands) — Amsterdam’s conversational-AI health startup Caro Health acquired by US-based HOPCo; Caro’s team to expand HOPCo’s European digital division and integrate across products.

On the press

Automated insulin delivery — Utrecht’s ViCentra says its next-gen closed-loop Kaleido system is slated for a Europe launch next year, signaling more AID competition on the continent.

UK devices policy — MHRA opens a stakeholder survey on the Health Institution Exemption (HIE), floating extensions to community/home use and tighter PMS/governance—practical for hospital “in-house” SaMD/device teams.

Macro: Italy watch — New data show Italy’s tech funding momentum; healthtech has already raised ~$126M in 2025, underlining ongoing digital health demand.

One thing to remember

AI-heavy workflow tools are getting their first cheques (imaging, concussion safety) while cross-border consolidation (Caro→HOPCo) accelerates go-to-market—set against a UK policy tweak that could legitimize more hospital-built software/devices beyond the hospital walls. If you’re raising: show path to deployment (pilots, CE status) and a plan for integration into care pathways.


This content has been enhanced with GenAI tools.

Categories
Digital Health MedTech

Poland’s healthtech has outgrown ‘nearshore’: 10 products and 10 global hubs

A network of interconnected digital health hubs in Poland, showcasing advanced healthtech and pharma IT innovations with professionals collaborating in futuristic environments.

Stop calling Poland a nearshore

Poland isn’t just shipping code for someone else’s roadmap. It’s producing digital health products used by tens of millions, and it’s hosting serious pharma/biotech tech operations—not just shared services. If you still think of it as a low‑cost back office, you’re reading a 2015 brochure.

Poland healthtech at a glance

MetricSnapshotSource
Healthcare marketPLN 191bn (~$52bn) (2023); projected 8.3% CAGR (2023–2028)Strategy& 2024
Medtech market (CEE)$11bn, largest in CEE; projected $13.8bnPAIH MedTech
Digital railsIKP, e‑Prescription (mandatory since 8 Jan 2020), e‑Referral (mandatory 2021)CeZ, e‑Rx analysis, policy
Enterprise hubs10+ pharma/medtech hubs (Roche, GSK, Bayer, Moderna, Astellas, BI, GEHC, Philips, Fresenius, AZ)Examples and links below

Polish products to watch (scale & potential)

CompanyWhat it doesScale / tractionMarkets & notes
DocplannerMarketplace + SaaS for clinics80m patients/month, 260k active doctors, 22m bookings/mo, 13 countriesEntered DACH via jameda acquisition
InfermedicaAI symptom‑to‑triage & intake86% user satisfaction; 76% intent to follow guidanceUsed by payers incl. Techniker Krankenkasse
DiagnostykaDiagnostics network1,100+ collection points, 156 labs; PLN 1.6bn revenue (2023); IPO priced at PLN 105; debut 7 Feb 2025Reuters
LabplusAutomated lab‑result interpretationIntegrated with leading labs incl. Diagnostyka partnershipB2B/API model across lab networks
CardiomaticsAI for Holter/long‑term ECGCE‑marked; clinician time savings reportedStudy overview
StethoMeAI‑enabled home stethoscopeCE‑marked lung‑sound analysis; remote respiratory careDeployed in telehealth programmes
AioCareConnected spirometryValidated in primary carePubMed
Saventic HealthAI for rare‑disease detectionEU roll‑out; €1.9m funding (2024)EU‑Startups
BrainScanAI for brain CT (stroke/trauma)2024 expansion across EMEAIndustry coverage
Jutro MedicalAI‑first hybrid primary care€12m Series A (2025) to expand EUEU‑Startups

Enterprise gravity: big pharma/medtech tech now runs through Poland

CompanyCityWhat happens hereScale (where stated)Source
RocheWarsaw & PoznańGlobal IT Solution Centre; Regional Clinical Trials Centre; Global Procurement Hub1,250+ employees in PolandRoche Poland
GSKWarsaw & PoznańGlobal Regulatory Centre; global trials coordination; Tech/Cyber600+ employeesGSK Poland footprint 2024
BayerWarsawDigital Hub building data platforms & productsup to 400 IT roles plannedAnnouncement, Hub page
ModernaWarsawInternational Business Services (finance, PV, HR, digital)~160 roles targetPress release
AstellasWarsawGlobal Capability Centre (2025)New hubLeadership news
Boehringer IngelheimWrocławGlobal Business Services centreLaunched 2022GBS page
GE HealthCareKrakówCommand Center software developmentPlatform in 290+ hospitalsGEHC Command Center
PhilipsŁódźGlobal Business Services hubOne of 7 global hubsPhilips GBS
Fresenius (FDT & FMC)WrocławDigital Technology & GBS hub for EMEAScaling teamsFresenius DT Poland,
AstraZenecaWarsawGlobal Clinical Trials CentrePart of AZ’s global networkAZ Poland

Why Poland now (and why it matters for commercialisation)

  • Public digital rails are in place. e‑Prescription has been mandatory since 8 January 2020; e‑Referrals became mandatory in 2021. The national P1 platform under Centrum e‑Zdrowia (CeZ) powers services like IKP/mojeIKP across the system.
  • Talent density × EU proximity. A deep engineering pool with multinationals co‑locating product and data teams in Warsaw/Poznań lowers integration costs across EMEA.
  • Export DNA. Docplanner’s acquisition of jameda shows a practical route: build in Poland, expand via M&A into regulated EU markets to accelerate trust and supply‑side liquidity.

Quick Q&A: for operators and investors

Is Poland still just a ‘nearshore’ play? No. Platform leaders (Docplanner, Infermedica) and 10+ pharma/medtech hubs now concentrate product‑adjacent work in Poland: engineering, data, regulator not only SSC/BPO.

What’s the biggest commercial bottleneck domestically? Limited, inconsistent NFZ pathways for digital health; most early revenue is private pay or export. Limited purchasing power within market. Treat Poland as an R&D and proof‑of‑value market; monetise in DACH/UK.

Best route to scale across Europe? Build MDR‑ready from day one, localise for DE/IT/ES, and consider controlled M&A to enter regulated markets (see Docplanner → jameda).

What metrics matter? Adoption proxies (e.g., Infermedica’s satisfaction and intent to follow guidance), conversion to appropriate care, reduced waiting time, and clinician time saved.

Playbook for founders and operators

  • Build for export from day one. Multilingual, MDR‑ready, and priced for DACH/UK.
  • Piggyback on the hubs. Partner with Roche/GSK/Bayer/Moderna teams locally for pilots, data pipelines, or co‑dev—your buyer is often already in Warsaw.
  • Measure what matters. Track adherence, conversion to appropriate care, and time‑to‑diagnosis—Infermedica’s adoption proxies are a good template (2024 data).

Bottom line

Poland isn’t Europe’s healthtech subcontractor anymore. It’s a product‑making, enterprise‑integrated node.
The smart money will treat Warsaw and Poznań as launchpads, not low‑cost destinations.

This content has been enhanced with GenAI tools.

Categories
Digital Health MedTech

Europe MedTech & Digital Health Weekly Brief #1

(Week of Aug 2–8, 2025)

August might be peak out-of-office, but Europe’s medtech builders didn’t pack it in. Cardiology AI is scaling, workflow AI is cutting admin drag, and evidence-backed devices are crossing borders.

People

    Marta Gaia Zanchi, Founding Partner at Nina Capital, Source: Nina Capital

    Investor POV:
    Marta Gaia Zanchi, Founding Partner at Nina Capital, speaking on healthtech hype vs. reality—data moats, regulatory timing, and evidence as currency shaping founder and LP conversations.

    Money flows

      Ross Upton, Ultromics Founder and CEO. Source: Ultromics.com

      Ultromics raised  $55M for AI cardiology diagnostics — Oxford-based echocardiography AI scaling decision support for earlier detection and heart failure insights across NHS/EU care.
      Listen to this interview with Ultromics Founder and CEO Ross Upton.

      SNIPR Biome logo. Source: SNIPRBiome website.

      SNIPR Biome gets €35M injection to advance CRISPR therapies for antimicrobial resistance. In this round there are new backers such as the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D)


      Oliver Åstrand, CTO; Oscar Boldt-Christmas, CCO; Lukas Saari, CEO; Founders of Tandem Health. Source: www.tandemhealth.ai

      Tandem Health secures $50M to build an AI-native operating system for clinical workflows across Europe.

      On the press

        One thing to remember

        In 2025 Europe, the fastest route from “cool demo” to “signed contract” is evidence-backed AI or devices that save clinician time and improve outcomes.

        Founders: design for clinical workflows, not just pilots; document outcomes and time-saved like it’s your superpower; pair dilutive with non-dilutive where it speeds trials and procurement.

        Investors: back teams converting regulatory readiness and real-world evidence into purchase orders—and keep an eye on AI companions where engagement meets adherence. Europe’s healthtech summer is quiet but compounding.

        This content has been enhanced with GenAI tools.